Multi-center Study to Assess Safety, Tolerability and Efficacy of MBN-101 in Patients With Moderate/Severe DFI

Multi-center Study to Assess Safety, Tolerability and Efficacy of MBN-101 in Patients With Moderate/Severe DFI
Conditions:   Diabetic Foot Infection;   Diabetic Foot
Interventions:   Drug: MBN-101 topical;   Other: Standard of Care
Sponsors:   Microbion Corporation;   CUBRC, MTEC, and US Navy
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

June 30, 2022Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Comments